Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

Lung Cancer

Volumn 26, Issue 2, 1999, Pages 85-94

  Ten Bokkel Huinink, Willem W ^a   Bergman, Bengt ^b   Chemaissani, Assad ^c   Dornoff, Wolfgang ^d   Drings, Peter ^e   Kellokumpu Lehtinen, Piikko Liisa ^f   Liippo, K ^g   Mattson, Karin ^h   Von Pawel, Joachim ⁱ   Ricci, Sergio ^j   Sederholm, Christer ^k   Stahel, Rolf A ^l   Wagenius, Gunnar ^m   Walree, N V ⁿ   Manegold, Christian ^e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

^d Klinikum Mutterhaus der Borromaerinnen   (Germany)

^e Thoraxklinik   (Germany)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^j UNIVERSITY OF PISA   (Italy)

^k LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ ST ANTONIUS HOSPITAL   (Netherlands)

more..

Author keywords

Cisplatin; Efficacy; Etoposide; Gemcitabine; Non small cell lung cancer; Quality of life; Randomized Phase II study

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; METOCLOPRAMIDE; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032739808     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00067-7     Document Type: Article

References (22)

1. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., Rugg T.A. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1535-1540.
2. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1821-1826.
3. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. (American Joint Committee on Cancer). Manual for Staging of Cancer. 4th ed. Philadelphia: J.B. Lippincott Co., 1992.
4. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. J. Cancer. 30A:1994;635-642.
5. Bonomi P., Finkelstein D., Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol. 17:1994;215-217.
6. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., Blum R.H., Green M.D., Mason B. et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Oncology Group. J. Clin. Oncol. 7:1989;1602-1613.
7. Coates A., Abraham S., Kaye S.B., Sowerbutts T., Frewin C., Fox R.M. et al. On the receiving end - patients perception of the side-effects of cancer chemotherapy. Eur. J. Cancer. Clin. Oncol. 19:1983;203-208.
8. Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Costanzo, et al. A randomized trial of 3 cisplatin containing regimens in NSCLC. A study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990;26:52-6.
9. Dhingra H.M., Valdivieso M., Carr D.T., Chiuten D.F., Farha P., Murphy W.K. et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16 in the treatment of advanced NSCLC. J. Clin. Oncol. 3:1985;176-183.
10. Einhorn L.H., Loehrer P.J., Williams S.D., Meyers S., Gabrys T., Nattan S.R. et al. Random prospective study of vindesine versus vindesine plus cisplatin, plus mitomycin in advanced non-small cell lung cancer. J. Clin. Oncol. 4:1986;1037-1043.
11. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J.M. et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur. J. Cancer. 32A:1996;243-248.
12. Hainsworth J.D., Johnson D.H. Chemotherapy of advanced NSCLC: a randomized trial of three cisplatin-based chemotherapy regimens. Am. J. Clin. Oncol. 12:1989;345-349.
13. Klastersky J., Sculier J.P., Lacroix H., Dabouis G., Bureau G., Liebert P. et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced NSCLC. EORTC protocol 07861. J. Clin. Oncol. 8:1990;1556-1562.
14. Klastersky J., Sculier J.P., Ravez P., Libert P., Michel J., Vandermoten G. et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced NSCLC. J. Clin. Oncol. 4:1986;1780-1786.
15. Manegold C., Bergman B., Chemaissani A., Dornoff W., Drings P., Kellokumpu-Lehtinen P. et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small cell lung cancer. Ann. Oncol. 8:1997;1-5.
16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
17. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
18. Rosso R., Salvati F., Ardizzoni A., Gallo Curcio C., Rubagotti A., Belli M. et al. Etoposide versus etoposide plus high dose cisplatin in the management of advanced non-small cell lung cancer. Cancer. 66:1990;130-134.
19. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S., Creech R.H., Mason B.A., Joss R.A. et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J. Clin. Oncol. 4:1986;14-22.
20. Ruckdeschel J.C. The role of standard dose etoposide in the management of NSCLC. Semin. Oncol. 10:1992;39-44.
21. The WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation, 1979.
22. Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CA Jr., et al. A randomized trial of five cisplatin containing regimens in patients with metastatic NSCLC. A Southwest Oncology Group Study. J Clin Oncol 1991;9:1157-62.